Clinical Trial Update: Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of full-length parathyroid hormone PTH(1-84) and strontium ranelate on bone markers in postmenopausal women with primary os…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• PTH(1-84) (parathyroid hormone 1-84)
• Strontium ranelate (strontium ranelate)

Snippet

Sponsor: Nycomed | Conditions: Osteoporosis | Phase 4 | Status: COMPLETED | Results posted: 2011-06-28